Member Info for David1951c

This is now on Destiny's website. Hopefully they have a leading role to play.
destinypharma.com/2021/01/27/27-jan-2021-destiny-pharma-welcomes-matt-han****s-attention-to-amr/

Unsurprising given the delays and apparent uncooperative response from SAU. Parties being unable to agree suggests it could take quite a while longer and some PIs will re-invests elsewhere as there are so many other opportunities. Today £20k of sells has reduced the SP by more than 10% which shows how sensitive pricing can be and how AIM pricing methods contribute to volatility and more sells. Disappointing as I have nearly 1m shares but I will wait for this to complete.

Presentation is on Wednesday (27 January). I am not around but hopefully anything significant will be posted and presentation available later. News is due on XF73 study PIIb before end of March so not too long to wait. Good to see the SP increasing and perhaps will be sustainable with presentation and news coming.

Hard to read why the SP rose so quickly from around 80p to 120p without major new news so the pull back is not such a big surprise here. More than 60% is in safe hands so the SP will move quickly on smallish volumes. Perhaps the momentum brought more speculative money in. Anyway it seems more stable today and it is an opportunity to buy or add with news expected by end of Q1. The fundamentals are good and the potential significant.

According to Money Week 8 Jan 2021, DT's share tips for 2020 returned - (minus) 1.3% way below many others. Hardly a good basis for decisions. Selling too early could be a big mistake but each PI makes their own decisions based on many factors. Today is a good opportunity to invest or top up given that news on P3 progress in other countries could come at any time and well before the home trials results in Q2. Hopefully IIs including Polar will build their positions in advance of major news.

Trek,
Useful to link ONC to possible development in this way especially with proteins. Good plug on SNG board!
It is also worth reminding the extent of ONC's Immunoinsights and breadth of their work with much potential.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments."
Hoping for more news before the results in less than four weeks.

There may also be news on possible subsidies which would be beneficial to overall funding and costs.
RNS 20 April 2020 mentioned them - see below but I cannot see any specific news.
"there are number of subsidies available to the Company which will have a significant impact on capital costs. These include on-mine exploration drilling programs, subsidised capital development for main access ways, productivity initiatives involving facilities and equipment and vertical shaft construction for ventilation. There are a range of subsidies related to mine support, water discharge, monitoring and safety equipment. In addition to all the subsidies which range from 40-60 percent of direct costs, there is substantial assistance offered for environmental initiatives. Whilst the Company intends to apply for various subsidies that are available and is optimistic for a positive outcome there can be no guarantee that these will be granted."
Perhaps there will be a comprehensive announcement updating everything by 26 January.

Previous H1 report was 20 December 2019 so in spite of Covid the latest could arrive at any time. With so many assets and a lot or work going on, an update could provide a further boost and also confirm it will be an excellent year for the company. After seeing what happened with a few other minor miners recently, hopefully Galileo will be in the charge forward.

Increased interest may be due to impending calendar year update, which was 21 January last time. I had this diaried for January to buy more especially after very encouraging update on 10 December 2020. Achieving profitability reduces the prospect for further fund raising and more dilution. Last week it was possible to buy for 1.20 so SP has come a long way. When the results are clearer it may be possible to attempt a valuation of the company. As it is a leader in its field, there must be a premium to the valuation.

The business and trading update on 10 December was very positive and momentum is growing. Last year the calendar year update was issued on 21 January which points to 2020 update next week or week after. With business getting into profit and strong growth forecast, this should be a point when SP makes a sustained rise reflecting the increase in value being created.

RNS 3 months ago said "With project financing, a mining licence and commencement of mine construction all imminent, Mahenge, and indeed Armadale, is on the cusp of transformation." Hopefully this does mean it could happen any time but looks a bit delayed. This may explain SP drift added in anticipation of news this month.

Dr. A - Hope you get an answer. Although the fund raise has thankfully so far not caused a major SP decline and in the medium to long term may mean quicker progress, those participating already have a significant paper gain denied to LTHs. This sort of situation happens with companies on AIM but should not be allowed.

Last calendar year trading update was on 21 January 2020 so expecting one next week. Moving into profit should be a catalyst for an increased valuation and MCap.

Dan - not sure any milestone payments have been received yet from CMS collaboration (interim accounts for June 2020 show no revenue) but perhaps these will come in 2021 - position unclear. CMS increased their holding since 1 Dec 2017 and now have 5.77%. CMS's Dr Peng is still on the board.
With the numerous strands to developments there should be a good flow of news before end of March.

aandi - sorry to learn that your holding is worth a lot less, presumably on paper. I believe the Wood reports are critical for EQTEC becoming really successful. Reports were expected by the company in Q4 and there appears to be a delay which is causing some investors to be nervous - me included. If the reports are good the company will be huge. If the reports are not so good the expansion will be slower. The technology works and will be rolled out. The scale and worldwide roll out would be more significant with Wood involved. I was hoping that at least the tech report would have been issued by now. Market report can come later.
Brave of you to have so many shares. I scaled down to reduce risk and only have 4m on almost a free carry. I am optimistic but have strict criteria to balance my pf.
Good luck and hopefully SP will be over 3p by end of January if reports are favourable.

No posts for second day confirms under some investors radar. The attractions include:
- Phase IIb results expected in Q1
- Fund raise last November so should be fully funded for foreseeable future
- Funds paid for acquisition that is complimentary and with progress expected this year
- Over 60% held in safe hands including professional investors in the sector such as Octopus

Potential is huge so high risk and reward for PIs. Good to see SP steadily rising.

Great news for me as only bought in last year (AIM). Lots of positives and with other prospects. RNS refers to modelling JORC at Big One which would be an in house effort. This shouldn't take long but how many weeks and would this need an external review or validation?

Hello Trek,

Thanks for comments. There are so many opportunities right now and choices have to be made. ONC is my third largest after Avacta and SNG (been in those 2 - 3 years). Have various others including DDDD, FAB, ORPH, VAL and N4P to which DEST has been added. Toyed with holdings in SAR, HEMO, TILS but sold out at a profit as got spread too thin. Financial position, potential and near term real news are important for me. Over recent years (until 2020) small biopharmas were often not rewarding. My first was VAL and it has also made a great pull back. Raising funds to keep going with consequent dilution has been an issue but some are nearer now than ever to coming good or at least holding their own.
Patience has been important with these and in other sectors e.g. EQT but I sold out too early in AFC and GGP albeit at a profit. Spare funds have also been invested in minor miners this year (about 10) as there is quite a lot going on there too. That has been spread thinly as again there are lots of opportunities on AIM on explorers and near producers such as GRL and BMV.
Back to ONC, I believe it has a lot more to give so I haven't sold any. Early lung blood tests are very promising and techniques can be developed for other cancers so that could lead to a number of years' development. I would like to see more clarity on earnings in 2021 and 2022 which could come with next results announcement. At some stage there might be need for more funds to accelerate the various developments. News from IMPACTT programme and profiling (RNS 6.10.2020) is also due soon. Outcomes of discussions with a number of biopharma customers will hopefully lead to further collaboration with some big names like Roche. The future is bright!

Hi Trek,
Waiting for news is frustrating but almost inevitable. ONC have much to offer and maybe an operational update across the whole would be on my wish list. Have you looked at Destiny Pharma where news is due in Q1?

Wood Group two reviews on the technology and the market were due to be completed in Q4. Wood are an excellent company and their reports will carry a lot of weight with potential customers and investors. I am waiting patiently for the reports and may add as the potential is huge. I have been a shareholder for over 2 years and want the company to succeed but are not ignoring that risks still exist.